Paul Feuerman, who joined AMRI in 2017, is responsible for leading all AMRI’s legal, mergers and acquisitions, and corporate affairs activities for the company’s locations worldwide, including the U.S., Europe and Asia.
Previously, Mr. Feuerman was assistant general counsel, global business development at Mylan, where he provided counsel in support of several business transactions including, but not limited to, the $1.6 billion acquisition of Agila global injectables and oncolytics businesses; the $5.3 billion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business; and HSR divestitures in support of the $7.2 billion acquisition of Meda. Prior to this, he served as General Counsel for SciDose LLC. Earlier in his career, he served as general counsel at Axonyx Inc. and executive vice president and general counsel at Schein Pharmaceutical Inc.
Mr. Feuerman holds a bachelor’s degree from Trinity College, Hartford, Conn., and earned a Juris Doctor degree from Columbia Law School, New York, N.Y.
